Comparative Pharmacology
Head-to-head clinical analysis: RECORLEV versus TRIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RECORLEV versus TRIOSTAT.
RECORLEV vs TRIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RECORLEV (levoketoconazole) is an orally administered corticosteroid biosynthesis inhibitor that suppresses cortisol production by inhibiting adrenal and gonadal steroidogenic enzymes, particularly CYP17A1 (17α-hydroxylase and 17,20-lyase) and CYP11B1 (11β-hydroxylase). It also weakly inhibits CYP3A4 and other CYP enzymes.
TRIOSTAT (liothyronine sodium) is a synthetic form of the thyroid hormone triiodothyronine (T3). It binds to thyroid hormone receptors in the nucleus, altering gene expression and increasing cellular metabolism, oxygen consumption, and heat production.
150 mg orally twice daily with a high-fat meal.
Adult: 5 mcg/kg IV every 8 hours. Adjust based on clinical response.
None Documented
None Documented
18 hours; prolonged in renal impairment (up to 45 hours in CrCl <30 mL/min)
2.5 days (terminal); shortened in hyperthyroidism, prolonged in hypothyroidism
Renal: 85% as unchanged drug; Fecal: 10% as metabolites
Renal (40% unchanged, 20% as liothyronine conjugates); fecal (35%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone